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Abstract 1 
Objective:  Patient activation can be measured using the Patient Activation Measure (PAM) developed by 2 
Hibbard et al, however, little is known about the uses of the PAM in research and in practice. This study 3 
aims to explore its differing utility in four UK exemplar sites.   4 
Methods :  Data from  four exemplars in a range of health settings with people living with long-term 5 
conditions (i.e. stroke or COPD) were evaluated. PAM scores were described and explored in relation to 6 
clinical and sociodemographic variables and outcome measures.  7 
 8 
Results: PAM scores illustrated that most with COPD or stroke reported PAM levels of 3 or 4, indicating 9 
that they are engaging, but may need help to sustain their scores.  The exemplars illustrate the utility of, 10 
and potential issues involved in, using PAM as a process/outcome measure to predict activation and the 11 
effectiveness of interventions, and as a tool to inform tailoring of targeted interventions.  12 
 13 
Conclusions:  The PAM tool has been shown to be  useful as an outcome measure, a screening tool to tailor 14 
education, or a quality indicator for delivery of care.   15 
Practice implications: However good demographic and patient history are needed to substantiate PAM 16 
scores.  Further work is needed to monitor PAM prospectively.     17 
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Background 1 
It is widely acknowledged that healthcare systems in the UK and worldwide are facing profound 2 
challenges. 1  In the UK, the English National Health Service  (NHS) five year forward view2  states that due 3 
to an increasingly ageing population, 3  the increasing prevalence of multiple long-term conditions 4,5  and 4 
the limits to the available financial resources new models of care are needed to face the demands of the 5 
current population.  Globally, there have been moves towards a culture of patient engagement and self-6 
care with an  expectation that systems will be redesigned to be  more patient-centred, based on  needs, 7 
priorities and experiences where decision making and care planning is  in partnership between patients and 8 
professionals,  6-8  such as the  House of Care model. 9   The house of Care model is a coordinated delivery 9 
system for personalised care and support planning across multiple partners and sectors.   10 
Measuring the quality and effectiveness of person-centred care, however, has its challenges. 1   A wide 11 
variety of PROMS (Patient Reported Outcomes Measures) and PREMS (Patient Reported Experience 12 
Measures) exist to measure service performance and quality indicators, or patient outcomes such as 13 
quality of life and self-management. 10,11  There is, however, no one ‘right’ way, and a general lack of clarity 14 
about what we mean by ‘person-centred care’ 12 in order to start unpicking its components.  One area 15 
receiving growing attention across the UK’s NHS in relation to person-centred long-term condition 16 
management is the concept of patient activation and its measurement as an indicator of quality and 17 
effectiveness, but also as a tool to tailor and stratify the delivery of care or people at risk of poor self-18 
management.   19 
Patient activation or readiness to self-manage measures individuals’ understanding of their role in 20 
managing their health and their willingness and ability to take independent actions and decisions to 21 
manage their health and healthcare, 13,14  either self-directed or facilitated (but not driven) by professionals 22 
and/or peers.  Hibbard et al suggests that patient activation provides a better understanding of why some 23 
patients engage fully with their health and others do not. 12 Operationally, patient activation, can be 24 
measured by the Patient Activation Measure (PAM) , a 13-item scale developed by Hibbard et 25 
al, 15,16 designed to assess an individual’s knowledge, skill, and confidence with respect to managing his/her 26 
health.  The score ranges from 0-100, and determines how ‘activated’ a person is, as one of four stages 27 
(Level 1-4, where 1 is least activated, Figure 1).    International evidence demonstrates it has been used as 28 
an outcome to evaluate a vast array of self-management interventions 17, 18  across different long-term 29 
conditions and, different counties and cultures.  19-23  with some studies showing improvement in activation 30 
scores after interventions. 20,21,23 Studies have also shown that increases in patient activation are associated 31 
with a range of positive health outcomes, including reduction in body mass index, reduced blood glucose 32 
levels, reduced blood pressure and reduced cholesterol,24-27 and positive health behaviours with regards to 33 
decision making, health information seeking, engagement in health behaviour and lifestyle changes, uptake 34 
of preventative health care, and self-management. 15,16,28 35 
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It has been reported that the PAM can be used as: i) a process or outcome measure to determine the 1 
clinical or sociodemographic characteristics that may predict level of activation in order to improve patient 2 
engagement and health outcomes, with increases in activation being either an endpoint or a tool with 3 
which to improve other health outcomes, ii) a tool to inform tailoring of targeted interventions, by 4 
assessing an individuals’ capacity for self-management and enabling the type and amount of support 5 
required by the individual to be targeted towards this and, iii) an outcome measure in evaluating the 6 
performance and effectiveness of healthcare systems and interventions, by undertaking before and after 7 
evaluations of the person’s level of activation (also summarised in Table 1). 29 Recently, NHS England policy1 8 
has begun to advocate the use of the PAM as a ‘vital sign’ in addressing the challenge of providing high 9 
quality, person-centred, sustainable and cost effective long-term condition support.  To date, the PAM has 10 
been more frequently used elsewhere in the World and evidence to support this policy direction in the UK 11 
and its effectiveness and appropriateness within a UK, long-term condition management context has yet to 12 
emerge and be disseminated at a national and international scale.  In particular, we know little about how 13 
activated. (or not) populations with different long-term conditions across the UK are, how this changes 14 
over time and whether there clinical and sociodemographic factors can predict activation levels and 15 
changes in these.  We also know little about the utility of the PAM in helping to tailor the type and amount 16 
of self-management support individuals receive and its effectiveness as an outcome measure to determine 17 
the effectiveness of the interventions and services that we offer.   In this paper, we draw on evidence from 18 
four exemplar studies (two prospective studies and two secondary analyses) in which the utility of the PAM 19 
within a UK context in patients with long term conditions (in these examples, COPD or stroke) was 20 
explored.  This paper is amongst the first to report on the utility of the PAM within a UK context, ahead of 21 
the evidence from NHS England and the Health Foundation’s pilot and evaluation sites. 22 
 23 
 24 
 25 
 26 
 27 
  28 
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Methods 1 
Four exemplar data sets which involved the use of the PAM (permission received from Insignia Health 2 
(http://www.insigniahealth.com/solutions/patient-activation-measure) were identified and used.  The 3 
exemplar datasets utilised a variety of approaches, were undertaken in a range of settings and included 4 
people living with long-term conditions (i.e. stroke or COPD) (Table 2). The four exemplars used for this 5 
report were identified locally from clinical and academic colleagues, all of whom were using the PAM 6 
locally, two as part of funded research projects and two as part of service evaluations.   7 
The aims were to explore and describe PAM scores within populations with stroke or COPD, how these 8 
changed as a result of interventions and/or how they were associated with clinical and sociodemographic 9 
variables and how they were used in real life practice.  In reviewing the datasets collectively, it became 10 
clear that we could present descriptive evidence to illustrate how the PAM has been used in different ways 11 
within a UK context.   12 
 13 
Exemplar 1 -This was a single-site prospective cross-sectional study (CLCH NHS Trust, London, 2012).  A 14 
convenience sample of COPD patients attending for clinic or pulmonary rehabilitation appointments were 15 
used to maximise recruitment. Participants completed the study measure and  gave access to  notes for 16 
additional information (age, gender, disease severity (MRC Score), spirometry (where available), current 17 
smoking status, HADS (Hospital Anxiety and Depression Scale) score, number of hospital admissions and 18 
self-reported respiratory disease exacerbations in the previous 12 months).     19 
 20 
Exemplar 2 -  NHS Ayrshire and Arran (A&A) was a demonstration site for The Health Foundation’s Co-21 
Creating Health (CCH) initiative 30,31  which covered four clinical areas (COPD, depression, diabetes and 22 
muscoskeletal pain) and aimed to embed self-management support within UK services. The programme 23 
was delivered by an expert patient and clinician facilitators, (5 generic and one condition-specific sessions).     24 
Patients were identified from disease registers in primary care.  The PAM tool was administered pre and 25 
post-programme and then at 3, 6 and 12 months post programme.   This retrospective analysis focusses on 26 
COPD. 27 
Exemplar 3 –  This retrospective review of routine care in a pulmonary rehabilitation centre  (2013-2014). 28 
The pulmonary rehabilitation (PR) programme was an “opt-in” twice weekly 6 week self-management 29 
programme for patients with an individualised exercise programme and education component. The PAM 30 
measure was used as a group outcome measure administered anonymously pre-PR, post-PR, 6mth and 12 31 
mths. Patients were unmatched ‘events’.  32 
 33 
Exemplar 4 – This research project explored how the PAM could be used to tailor self-management support 34 
intervention for stroke survivors (3 months post stroke) in the community. 32  The intervention consisted of 35 
a tailored self-management action plan, incorporating an individualised assessment of stroke survivors’ 36 
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levels of activation (using the PAM), goal setting and motivational interviewing and the study reported on 1 
both stroke survivors’(n=6) and professionals’ (n=5) perspectives of the intervention and the use of the 2 
PAM to guide the provision of self-management support.  In this study, the PAM was not used as an 3 
outcome measure but rather a process tool to identify participant’s level of activation and align the 4 
provision of tailored support towards that based on the underpinning theory. 5 
Data analysis  6 
Descriptive statistics were used in estimating means or medians together with their respective standard 7 
deviations or inter-quartile ranges. These were reported using the appropriate summary estimates for all 8 
demographic and clinical variables as well as PAM scores for each set of study data.   All data were entered 9 
into and analysis carried out using SPSS (V.19.0).  ANOVA with post hoc Tukey HSD comparisons (Exemplar 10 
3), repeated measures ANOVA with a Greenhouse-Geisser correction (Exemplar 2),  multiple regression 11 
analysis (Exemplar 1), and Mann Whitney and  chi-square tests (Exemplar 1) were undertaken.  12 
 13 
Ethical approval 14 
 15 
Exemplar 1 and 4 obtained ethical approval from NHS ethics Committees (ref: 12/YH/0234) and (ref 16 
12/WS/0103). For Exemplar 2 and 3 approval was sought from R&D in each NHS Board and ethical approval 17 
was given by the SHLS ethics committee at Glasgow Caledonian University.   18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
  29 
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Results 1 
Table 2 summarises the characteristics and data from the four exemplars including two prospective studies 2 
and two retrospective secondary analyses of data previously collected from a Co-Creating Health site, and 3 
routine data from community care.  The PAM tool was used differently in each exemplar (Table 2), 4 
corresponding with the reported applications in the literature29  Table 2 shows the findings from each 5 
individual exemplar. 6 
Exemplar 1 7 
40 COPD patients participated in this prospective study (20 males mean age 68 SD±9.4, median PAM score 8 
56.4, IQR 27.1; FEV155.5%; MRC score =3.0±0.90; 12 current smokers).  60% had mild/moderate COPD, 9 
50% had severe/very severe COPD [27].  In total there had been 23 self-reported respiratory hospital 10 
admissions and 87 self-reported exacerbations in the last 12 months.   Most were attending for pulmonary 11 
rehabilitation (n=20), routine clinic appointment (n=16), or maintenance classes (n=4).  Those attending PR 12 
had a significantly higher PAM score compared to those attending clinic appointments (median 67.25 IQR 13 
28.3, vs median 52.9, IQR 10; p=0.023, Figure 2a) .  There were no significant differences between PAM 14 
Scores and disease severity (mild/moderate vs severe/very severe, (Mann Whitney p=0.389).    Multiple 15 
regression analysis using the PAM score identified three variables which gave the best model fit to predict 16 
PAM score, these included COPD severity, gender and exacerbation frequency (some missing data). 17 
Statistical assumptions of linearity, independence of errors, homoscedasticity, normality of residuals were 18 
met. Only one variable, exacerbation frequency was statistically significant in the prediction, p<0.05. 19 
 20 
Exemplar 2  21 
This retrospective dataset had matched data from 29 patients with COPD attending a self-management 22 
programme (Male 15, female 14, mean age 69.5 SD 8.6).   Median PAM scores were higher for post 23 
programme (compared to baseline) and then dropped at 3mths (baseline PAM Score 55.2 [IQR 17.2]; post 24 
programme 71.95 [IQR 23.6], 3 mths 56.4 [IQR 16.4].  Repeated measure ANOVA (GLM) for the overall 25 
score shows that there were significant differences between the means at the different time-points 26 
(Greenhouse-Geisser [F(1.976, 53.352)=7.164, p=0.002).  Post-hoc analysis shows there were significant 27 
differences between baseline and post-programme measurements (p=0.001) (Figure 2b) 28 
 29 
Examplar  3  30 
This retrospective analysis included PAM data from 231 individuals attending PR at three time points: 31 
baseline (n=128), 6 mths (n=65), and 12 mths (n=38).    During the same time-period 274 individuals 32 
attended PR and 188 completed 6 mth and 147 had a 12 mth follow-up.  Median baseline score pre-33 
pulmonary rehabilitation were 56.4 (IQR 14.8), at 6 and 12 months post rehabilitation the scores were 34 
63.2(IQR 14.4) and 63.2 (IQR20.1), respectively.  There were significant differences between baseline and 35 
six months (p<0.001), and baseline and 12 months (p<0.001, Figure 2c).   36 
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 1 
Exemplar 4  2 
PAM scores were not measured pre and post intervention in this study because the sample was very small 3 
and because the PAM was used as a process measure rather than an outcome measure.  The median PAM 4 
score was 76.4 (IQR 10.93) (Level 4), identifying that they were all ‘active self-managers who needed 5 
support only in times of stress or illness’ (Figure 1).  There were no significant differences in PAM Scores 6 
when comparing gender and Modified Rankin Scores (level of disability).  Despite the quantitative PAM 7 
scores, qualitative interviews reflected characteristics associated with lower PAM levels (e.g. Levels 1 and 8 
2, as shown in Figure 1).  Perceptions on the use of PAM in this study are reported elsewhere 32 however, 9 
briefly, stroke survivors perceived that the PAM had been easy and straightforward to follow but not 10 
specific enough to identify their personal abilities and needs i.e. it didn’t measure what was most relevant 11 
to the participants.  The professionals reported concerns that patients may give ‘socially desirable’ answers 12 
rather than a true reflection of their readiness to engage, as demonstrated by the discrepancy between the 13 
qualitative and quantitative data, and that the appropriateness of the wording may need reconsidered for 14 
a UK audience.  They perceived, therefore, that the PAM was less valuable as a tool for tailoring self-15 
management support interventions in this study. 16 
 17 
These 4 exemplars demonstrate how PAM can be used in a variety of ways and settings.  Closer inspection 18 
of Exemplar 2 and 3 where PAM is used as part of service evaluation, PAM is also used as an outcome 19 
measure to measure effectiveness of interventions.  Both analyses were retrospective, in Exemplar 3 data 20 
was  anonymised and only examined group effectiveness and in Exemplar 2 the data were individually  21 
matched.     Clinical data  from participants was not available  at both sites, and other details are limited 22 
around socio-economic variables, disease history etc.  At both sites the PAM was used purely to look at 23 
change pre and post intervention.  24 
 25 
Exemplar 1 used PAM as a process/outcome measure to predict engagement, a different approach from 26 
the service evaluations described previously.  This research project collected more clinical data with PAM 27 
which allowed richer analysis, however the same sample size and lack of repeat data collection makes 28 
further analysis difficult.   Exemplar  4 used the PAM as part of a mixed methods study, to inform tailoring 29 
of targeted interventions.   30 
   31 
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Discussion and Conclusion 1 
Discussion 2 
The potential use of the Patient Activation Measure as a tool for measuring the effectiveness of, or to aid in 3 
the tailoring of, interventions and care delivery is fast becoming of interest across the UK.  Existing data on 4 
its use, however, largely stems from the USA and therefore we know little about the feasibility and 5 
challenge of using the PAM within a UK context. 12   This prompted us to summarise data from four studies, 6 
conducted by the authors, using a case study approach to present data on PAM levels across groups of 7 
people living in the UK with COPD or stroke, and to illustrate examples of the different ways in which the 8 
PAM can be used, as articulated by Hibbard and Gilburt (2014). 29  The data in this report was drawn from 9 
different parts of the UK which is valuable since it contextualises its use within the UK’s devolved 10 
healthcare systems i.e. Scotland and England/Wales and within the UK’s current system of routine care and 11 
service delivery using two long term conditions.  It is also important to see the wide range of approaches 12 
and practices used, such as repeated measures after intervention, group responses, matching scores with 13 
qualitative data and looking for associations with socio-economic and clinical factors prior to interventions.  14 
Using aspects from all of these exemplars can be used to improve delivery of care and tailoring of 15 
interventions.  16 
 17 
This is the first report, to our knowledge, that presents information on current PAM levels within a UK 18 
population of people with long-term conditions.   What we have shown here is some of the pitfalls of using 19 
tools for service evaluation and research.  Some of the key issues are lack of access to clinical data in 20 
routine datasets, incomplete data and small datasets and the unreliability of repeated measures. There are 21 
often time issues around adding extra detail to routine measures and  of using data for multiple purposes.  22 
We acknowledge that the data is limited in its generalisability and that our interpretations must be treated 23 
with caution given their methodological limitations.  In these exemplars he majority of people with COPD 24 
and stroke in our studies reported PAM levels of 3 or 4, indicating that are engaging in self-management 25 
but may require different types of support to sustain this at different times in their journey.  These scores 26 
are similar to a telephone survey by Ellins et al, 33 who found in the UK, scores of 59.43 (stage 3) with nearly 27 
60% of those sampled reaching this stage (n=3000). Previous evidence on PAM suggests that variables such 28 
as gender, age and disease severity are important predictors of PAM scores and theoretically, their 29 
engagement in self-management.34-37 Although data indicated few associations, this is likely because the 30 
studies were significantly underpowered.  To our knowledge, exacerbation frequency has not previously 31 
been investigated in association with PAM and self -management skills for those with COPD.  Further 32 
research is clearly needed to validate this finding in datasets which are optimally powered to detect such 33 
differences.  Understanding baseline PAM levels can enable health professionals to tailor their care, 34 
education and treatment to suit individuals’ level of engagement or readiness. This may include screening 35 
prior to pulmonary rehab to delay or advance referral or to tailor learning materials for educational 36 
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programmes.  Thus, the findings reported on here help to offer some support for the potential use of PAM, 1 
within a UK context, as a tool to identify and stratify those most in need of anticipatory advice or support. 2 
 3 
The data identified that those who attended routine clinics only and those who hadn’t yet engaged with a 4 
Pulmonary Rehabilitation (PR) or self-management programme (exemplar 1), typically lacked confidence to 5 
engage in self-management and were not yet ‘active self-managers’.  However following engagement with 6 
a pulmonary rehabilitation or self-management programme, scores were generally higher at Level 3 or 4, 7 
which may demonstrate increased confidence after the self-management or pulmonary rehabilitation.  8 
Data from participants following stroke (exemplar 4) had very high PAM Scores, higher than the COPD 9 
patients, this may be in part because of the acute nature of a stroke event, compared with the gradual 10 
development of COPD for example, or because of the intensive treatment and rehabilitation that people 11 
would have received shortly after the stroke event.  Although it is not possible to determine a causal link, 12 
the data - taken collectively – suggests that PAM could be used to stratify and identify who may benefit 13 
most from, and engage with, programmes for PR and self-management.  Our data also identifies that PAM 14 
can be used as a useful outcome measure to evaluate the effectiveness of existing services and 15 
interventions (exemplars 2 and 3).  However, Brewster et al 12 caution that increases in PAM scores are 16 
likely to be more demonstrable in those who were low to begin with; which is comparable with some of 17 
the international evidence.  We also echo the concerns of Brewster et al12 who acknowledge that increases 18 
in PAM scores may not necessarily be the best indicator of an effective, and more importantly, person-19 
centred service or intervention and that maintaining PAM score, rather than increasing it, may be a positive 20 
outcome.  Indeed, our data indicated that the initial peak in PAM scores seen after PR and self-21 
management programmes were not sustained over time (Exemplar 2).  Further research is needed to 22 
explore this and to understand how PAM levels change and how they can best be sustained over time with 23 
timely and appropriate models of follow up. 24 
 25 
The fourth exemplar specifically explored the feasibility and acceptability of using PAM as a basis for 26 
guiding the provision of tailored self-management support for stroke survivors. 32 Tailored coaching is not 27 
widely used as yet in the UK and there is little published evidence on this although it does hold potential 28 
and is of growing interest to researchers, practitioners, service providers and commissioners given the 29 
need to be more cost effective with resource use.  This data illustrated that although PAM was useful for 30 
gauging PAM levels across a group of stroke survivors, some found it challenging to complete and the 31 
stroke nurses delivering the intervention reported that it did not enable tailoring of appropriate care and 32 
support.  Thus, further research is needed to understand more about whether the PAM translates 33 
sufficiently to a UK population, and indeed groups of people with specific long-term conditions, and 34 
whether the elements of the PAM are specific enough to capture the outcomes that are most important to 35 
these groups in relation to their self-management. 36 
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 1 
Conclusions  2 
The data reported on here, has illustrated some examples of the ways in which the PAM could be used 3 
within a UK context; as a process/outcome measure to level of predict activation/engagement, as an 4 
outcome measure in effectiveness of interventions/services, and as a tool to inform tailoring of 5 
interventions. Interest in its roll out across the UK is considerable and has drawn particular support from 6 
groups representing patients e.g. National Voices, the International Alliance of Patients’ Organisations, as a 7 
tool to facilitate the delivery of person-centred care.  Our research identifies, however, that there is a 8 
wealth of robust research still required to be undertaken in order to fully understand the effectiveness and 9 
utility of PAM in a UK context.   10 
Practice implications 11 
The PAM tool is a potential tool which can be used both in research and service evaluation.  However the 12 
tool should not be used in isolation, and good demographic and patient history details need to be recorded  13 
regularly and repeatedly to understand the basis for the PAM scores and the changes that might be evident 14 
over time. 15 
 16 
Acknowledgements 17 
The Carnegie Trust for the Universities of Scotland provided research funding for the prospective study 18 
(Exemplar 1).  The Burdett Trust for Nursing provided funding for the stroke exemplar (Exemplar 4).  19 
Exemplars 2 and 3 were unfunded.  20 
11 
 
References 1 
 2 
1.  De Silva D. Helping measure person-centred care: A review of evidence about commonly used 3 
approaches and tools used to help measure person-centred care. London: Health Foundation. 2014  4 
2.   England, NHS. Five year forward view. London: HM Government. 2014  5 
3.  Barnett K, Mercer SW, Norbury M, WattG, WykeS, Guthrie B. Epidemiology of multimorbidity and 6 
implications for health care, research, and medical education: a cross-sectional study. The Lancet 7 
2012; 380:37-43. 8 
4.   Berzins K, Reilly S, Abell J, Hughes J and D Challis.  UK self-care support initiatives for older patients 9 
with long term conditions: a review. Chronic Illn2009;5: 56–72. 10 
 5.   Scottish Government. Improving health and wellbeing of people with long term conditions in Scotland: 11 
An action plan. Edinburgh 2009 12 
6.  De Silva D.   Evidence: Helping people help themselves: A review of the evidence considering whether 13 
it is worthwhile to support self-management. London:  Health Foundation 2011. 14 
7.  Coulter A, Roberts S, Dixon A. Delivering better services for people with long-term conditions: building 15 
the house of care. London: The King’s Fund. 2013  16 
8.   De Silva  D. Helping people share decision making. London:  Health Foundation. 2012 17 
9.   Coulter A., Roberts S, & Dixon A. Delivering better services for people with long-term conditions: 18 
building the house of care. The Kings Fund  2013 19 
10.  De Silva D. Measuring patient experience. London: The Health Foundation. 2013 20 
11. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr A J. The routine use of patient reported outcome 21 
measures in healthcare settings. BMJ 2010;340 c186(2a.)   22 
12.  Brewster J, Ramcharan P. Enabling and supporting person-centred approaches Learning 23 
Disability 2005; 491. 24 
13. Hibbard JH, Cunningham P. How Engaged Are Consumers in Their Health and HealthCare, and Why 25 
Does it Matter?  Center for Studying Health Systems Change Research Brief October 2008. 26 
http://www.hschange.com/CONTENT/1019/ 27 
14. Greene J. Hibbard JH. Why does patient activation matter?  An examination of the relationships 28 
between patient activation and health-related outcomes. Journal of General Internal Medicine 2012; 29 
27.5: 520-526. 30 
15.  Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): 31 
conceptualizing and measuring activation in patients and consumers. Health Serv Res.   2004; 39:1005-32 
1026. 33 
16.  Hibbard JH, Mahoney E, Stockard J, Tusler M. Development and testing of a short form of the Patient 34 
Activation Measure (PAM). Health Serv Res. 2005;40:1918-1930.  35 
17. Adams S, Goler NC, Sanna RS, Boccio M, Bellamy DJ, Brown SD, Neugebauer RS, Ferrara A, Wiley  DM, 36 
Schmittdiel JA. Patient Satisfaction and Perceived Success with a Telephonic Health Coaching Program: 37 
12 
 
The Natural Experiments for Translation in Diabetes (NEXT---D) Study.      Prev Chronic Dis 2013; 1 
10:130116  2 
18.  Deen D, Lu WH, Rothstein D, Santana L, Gold MR. Asking questions: The effect of a brief intervention in 3 
community health centers on patient activation. Patient Education and Counseling 2011; 84:257-60 4 
19. Richmond group of charities, King’s fund.  From vision to action:  Making patient-centred care a reality. 5 
2012 www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/Richmond-group-from-vision-to-6 
action-april-2012-1.pdf 7 
20.  Shane-McWhorter L,  McAdam-Marx C,  Lenert L,  Petersen M,  Woolsey S, ; Coursey JM,  Whittaker TC,  8 
Hyer C; LaMarche D; Carroll P,  Chuy L   Pharmacist-provided diabetes management and education via 9 
a telemonitoring program J Am Pharm Assoc  2015;  55:516-526.  10 
21.  Ehde DM,  Elzea J,  Verrall AM,  Gibbons LE, Smith A,  Amtmann D.  Efficacy of A Telephone-Delivered 11 
Self-Management Intervention For Persons With Multiple Sclerosis: a Randomized Controlled Trial 12 
With a One-Year Follow-Up  Arch Phys Med Rehabil. 2015; 96:1945-1958  13 
22.  Juul L, Andersen V J, Arnoldsen J, Maindal H T. Effectiveness of a brief theory-based health promotion 14 
intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a 15 
community setting. Primary care diabetes 2015 in press 16 
23.  Turner AP,  Anderson J K, Wallace  L M, Kennedy-Williams P. Evaluation of a self-management 17 
programme for patients with chronic obstructive pulmonary disease.  Chronic respiratory disease 18 
2014, 1479972314539979. 19 
24. Remmers C, Hibbard J, Mosen DM, Wagenfield M, Hoye RE, Jones C.. Is patient activation associated 20 
with future health outcomes and healthcare utilization among patients with diabetes? The Journal of 21 
ambulatory care management 2009; 32: 320-327. 22 
25. Rogvi S, TapagerI, Almdal TP, Schiøtz, ML,  Willaing I. Patient factors and glycaemic control–23 
associations and explanatory power. Diabetic Medicine 2012; 29: e382-e389. 24 
26. Skolasky RL, Mackenzie E.J, Wegener ST,  Riley LH.. Patient activation and functional recovery in 25 
persons undergoing spine surgery. The Journal of Bone & Joint Surgery 2011; 93: 1665-1671. 26 
27.   Terry PE, Fowles J B,  Harvey L. Employee engagement factors that affect enrollment compared with 27 
retention in two coaching programs—the ACTIVATE study. Population Health Management 2010; 28 
13.3: 115-122. 29 
28. Hibbard J H., Mahoney ER, Stock R,  Tusler M.. Do Increases in Patient Activation Result in Improved 30 
Self-Management Behaviors? Health services research 2007; 42: 1443-1463. 31 
29.  Hibbard JH, Gilburt H.. Supporting people to manage their health: an introduction to patient activation.  32 
London The Health Foundation 2014 33 
30.  Wallace, L. Co-creating health: Evaluation of the first phase. The Health Foundation, 2012. 34 
31. NHS Ayrshire and Arran Local evaluation for Co-creating health 35 
 http://www.health.org.uk/sites/default/files/CoCreatingHealth_NHSAyrshireArran_evaluation.pdf 36 
(accessed 4 November 2015) 37 
13 
 
32.  Kidd L, Lawrence M, Booth J, Rowat A and Russell S  Development and evaluation of a nurse-led, 1 
tailored stroke self-management intervention. BMC Health Services Research 2015 (in press) 2 
33.  Ellins, J, Coulter A. How engaged are people in their health care? Findings of a national 3 
telephone survey. The Health Foundation 2005. 4 
34.  Cameron J, Worrall-Carter L, Riegel B, Lo SK, Stewart S  Testing a model of patient characteristics, 5 
psychologic status, and cognitive function as predictors of self-care in persons with chronic heart 6 
failure. Heart Lung 2009; 38: 410–418.  7 
35.  Rose M, Fliege H, Hildebrandt M, Schirop T,  Klapp B F. The network of psychological variables in 8 
patients with diabetes and their importance for quality of life and metabolic control. Diabetes 9 
Care 2002; 25: 35-42. 10 
36.  Connelly CE. An empirical study of a model of self-care in chronic illness. Clinical Nurse Specialist 11 
1993; 7 : 247-253. 12 
37.   Disler RT, Gallagher RD, Davidson PM Factors influencing self-management in chronic obstructive 13 
pulmonary disease: an integrative review. Int J Nurs Stud 2012; 49: 230–242. 14 
 15 
 16 
 17 
 18 
  19 
14 
 
Figure 1 Description of the Hibbard’s four stages of the Patient Activation Framework 15 
 
 
 
 
 
 
 
Level1 (score 0-47) 
Individuals do not believe 
they can play a role in their 
own health and believe the 
doctor or nurse will ‘fix’ 
them.  They lack a basic 
understanding of their 
condition, treatment and 
self-management options  
 
Level 2 (score 47.1-55.1) 
Individuals typically 
understand they can be 
involved in their healthcare 
but lack the confidence and 
knowledge to self-manage  
 
Level 3 (score 55.2-67.0) 
 
Individuals may have the basic 
facts about their condition and 
its treatments 
Individuals are beginning to 
take action but may lack 
confidence 
 
Level 4 (score 67.1-100) 
Individuals typically have 
the confidence and skills to 
manage their health but 
may need help maintaining 
this under times of stress or 
threats to their health 
Figure 2a  Exemplar 1 
 
 
 
 Represents “out” outliers  
  *     Represents “far out” outliers   
 
P=0.023 
 Figure 2b Exemplar 2:  PAM Scores before and after a disease-specific self-management programme 
 
   Represents “out” outliers  
 
P=0.001 
N=28 N=28 N=28 
Figure 2c Exemplar 3:  Unmatched PAM Scores before and after pulmonary rehabilitation 
 
 
 Represents “out” outliers 
 
 
N=128 N=65 N=38 
P<0.001 
P<0.001 
Table 1 Uses of PAM tool 29 
 
- as a process or outcome measure to determine the clinical or sociodemographic characteristics that 
may predict level of activation in order to improve patient engagement and health outcomes, with 
increases in activation being either an endpoint or a tool with which to improve other health 
outcomes.   
- as a tool to inform tailoring of targeted interventions, by assessing an individuals’ capacity for self-
management and enabling the type and amount of support required by the individual to be targeted 
towards this and,  
- as an outcome measure in evaluating the performance and effectiveness of healthcare systems and 
interventions, by undertaking before and after evaluations of the person’s level of activation 
 
 
Table 2  
Exemplar 1 -PAM as process/outcome measure to predict activation/engagement 
 
Study Aim& Setting  Participants  Study Design & Sampling Methods& Analysis  Results & Limitations 
Study aim:   
 
To determine PAM 
levels within COPD 
populations and to 
identify 
associations with 
clinical and 
sociodemographic 
variables  
 
 
 
 
40 COPD patients were recruited 
to this prospective study (20 
males mean age 68 SD±9.4, 12 
current smokers) with a mean 
percent predicted Forced 
Expiratory Volume in one second 
(FEV1) of 55.5%,  and a mean 
MRC score of 3.0±0.9. 24 had 
mild/moderate COPD, 16 had 
severe/very severe COPD.  In 
total there had been 23 self-
reported respiratory hospital 
admissions and 87 self-reported 
exacerbations in the last 12 
months. 
 
Respiratory clinics (n=16) 
Mean age 66.4 ± 8.9, 8 Females  
8 Males , 7 current smokers 
 
Pulmonary rehabilitation 
programmes (n=20) 
Mean age 66.9±9.9, 12Females  
8Males, 5 current smokers 
 
Post-pulmonary rehabilitation 
maintenance classes (n=4) 
Mean age 70.3±7.1,  4 males, no 
current smokers 
 
Study design and location:  Single 
site, observational prospective cross sectional 
study (June-Aug 2012) 
 
Central London Community Healthcare NHS Trust 
(England) 
 
 
Study recruitment: Participants with COPD were 
identified by the Respiratory Consultant and 
recruited from  three settings using convenience 
sampling: 
i) respiratory outpatient clinics (hospital-
based)/ community respiratory clinics, 
ii) pulmonary rehabilitation programmes (at 
multiple locations), or 
iii)  iii) post-pulmonary rehabilitation gym 
sessions. 
The consent also requested permission to access 
the pulmonary rehabilitation and medical notes for 
additional information.  
 
Pulmonary rehabilitation [PR, a condition specific 
supported self-management programme]  
At this site PR was a rolling programme (with 
participants attending twice a week for six weeks).   
Participants had to be aged 18 years and over, able 
to speak and read English, provide written 
informed consent and deemed medically fit to 
participate.  No further eligibility criteria such as an 
upper age limit were put in place.  Those attending 
PR had to fit entry criteria to be eligible to 
participate 
 
Study sampling:  convenience sampling  
 
Ethical approval:  Yorkshire & The Humber – Leeds 
West ethics Committee (ref: 12/YH/0234). 
 
Participants completed the 
PAM tool before or after their 
appointment.  Age, gender, 
disease severity (MRC Score), 
spirometry, current smoking 
status, HADS (Hospital, Anxiety 
& Depression Scale) score, 
number of hospital admissions 
and self-reported respiratory 
disease exacerbations in 
previous 12 months) was 
collated from the medical 
notes. 
 
An exploratory multiple 
regression analysis was 
undertaken, with the 
dependent variable of 
activation for self-management 
(adjusted PAM score). 
COPD severity (MRC score), 
age, gender, 35 and also 
included exacerbation 
frequency, and smoking status 
were used in the regression 
analysis using a backward 
elimination method.  
 
Mann Whitney statistical tests 
were used for non-parametric 
comparisons and chi-square 
tests  for categorical 
comparisons. 
 
There was a statistically significant 
difference in the PAM score between 
those attending for respiratory clinics  
(median 52.9, IQR 10)(Level 2) and 
those attending for pulmonary 
rehabilitation (median 67.25 IQR 28.3) 
(Level 3) (p=0.023, Figure 1a). There 
were no significant differences 
between PAM Scores and disease 
severity (mild/moderate versus 
severe/very severe, (p=0.389).   
From the exploratory multiple 
regression analysis three  variables 
were found to provide the best model 
fit predicting adjusted PAM score.  
These  were COPD classification 
severity, gender and exacerbation 
frequency (limited data 27 entries)  
These three variables did not 
statistically significantly predict 
adjusted PAM score, F(3,23) = 2.936, 
p=.055, adj. R2 = .183, a likely 
consequence of the low number of 
subjects.   Only one variable, 
exacerbation frequency was 
statistically significant in the prediction 
(associated with lower PAM scores), 
p<0.05. 
 
Limitations: Small sample size, 
convenience sample, single site study, 
cross sectional so no causal links can be 
claimed, sample selection by 
respiratory consultant (possible 
gatekeeping) 
Exemplar 2 - PAM as outcome measure in effectiveness of interventions/services 
 
Study Aim& Setting  Participants  Study Design & Sampling Methods& Analysis  Results & Limitations 
To determine PAM 
levels within COPD 
populations and 
changes in PAM 
scores before and 
after self-
management 
intervention  
 
 
29 COPD patients  
 
[Male 15, female 14, mean age 
69.5 SD 8.6).   
 
    
 
Study design and location:  secondary retrospective 
analysis of existing data collected  from one 
demonstration site for The Health Foundation’s Co-
Creating Health (CCH) programme (2007-2012) (for 
COPD patients only), Ayrshire and Arran, Scotland.30  
 
Study recruitment:  As part of the CCH programme, 
participants with COPD, were identified from GP 
registers and invited to attend a self-management 
programme (consisting of four generic and one 
disease-specific sessions) (Moving On Together). 31  
 
Ethical Approval:  NHS Ayrshire and Arran 
(Scotland), R&D management approval  
 
Participants were asked to 
complete the PAM before 
starting the self-management 
programme (baseline, pre-
programme) and then 
immediately post-programme 
and at 3, 6 and 12 months post 
programme.  Matched patient 
data examined at each 
timepoint.  
 
Descriptive statistics were 
calculated, means, medians 
together with their respective 
standard deviations or inter-
quartile ranges. Summary 
estimates were reported for all 
demographic and clinical 
variables as well as PAM scores 
for each time point.   All data 
were entered into and analysis 
carried out using the software 
program Statistical Product and 
Service Solutions (SPSS) 
(V.19.0). Repeated measures 
ANOVA with a Greenhouse-
Geisser correction was 
undertaken   
Median PAM scores were higher for post 
programme (compared to baseline) and 
then dropped at 3mths (baseline PAM 
Score 55.2 [IQR 17.2] (Level 3); post 
programme 71.95 [IQR 23.6] (Level 4), 3 
mths 56.4 [IQR 16.4] (Level 3).  Repeated 
measure ANOVA (GLM) for the overall 
score shows that there were overall 
significant differences between the means 
at the different time-points (Greenhouse-
Geisser [F(1.976, 53.352)=7.164, p=0.002).  
Post-hoc analysis shows there were 
significant differences between baseline 
and post-programme measurements 
(p=0.001) (Figure 1b). 
 
 
Limitations: Small sample size, secondary 
analysis of retrospective data, no control 
group, some data not available for all 
variables for each participant. 
Exemplar 3 - PAM as outcome measure in effectiveness of interventions/services 
Study Aim& Setting  Participants  Study Design & Sampling Methods& Analysis  Results & Limitations 
To determine PAM 
levels within COPD 
populations and 
changes in PAM 
scores before and 
after rehabilitation 
programme  
 
Patients attending for 
pulmonary rehabilitation over a 
12 month period Jan 2013 to 
Feb 2014 
 
 
 
 
Study design and location:  secondary retrospective 
analysis of existing, anonymised data collected as 
part of routine care in a pulmonary rehabilitation 
centre, NHS Lothian 
 
Study recruitment: As part of the rehabilitation 
programme, participants with COPD were invited to 
take part in the 6-week programme, twice-weekly 
Participants were asked to 
complete the PAM before 
starting the rehabilitation 
programme and then 
immediately post-programme 
and at 6 and 12 months post 
programme.   
Anonymised paper copies with 
Median baseline score pre-pulmonary 
rehabilitation were 56.4 (IQR 14.8) (Level 
3), at 6 months post rehabilitation the 
scores were 63.2(IQR 14.4) (upper end of 
Level 3) and at 12 months the scores were 
63.2 (IQR20.1) (upper end of Level 3).  
There were significant differences between 
PAM scores at baseline and six months 
  
 
 
 
 
self-management programme, comprising 
individualised exercise programme and education. 
 
 Study sampling: 274 individuals attended PR  during 
this time period approximately 274 individuals 
attended PR and 188 completed 6 mth and 147 had 
a  12 mth follow-up.  
Patients completed the PAM measure anonymously 
at several timepoints. 
 
 
Ethical approval:  NHS Lothian,  R&D approval 
obtained)  
 
details of the appointment type 
(Baseline, 6 months or 12 
months) were analysed for this 
report. 
 
Patients were unmatched 
‘events’ and 231 PAM 
measurements were available 
in total for analysis from the 
274 attendees. 
 
n=128 measurements at 
baseline, n=65 measurements 
at 6 mths, and n=38 
measurements at 12 mths.    
 
Each measurement relates to 
an individual attending the PR 
programme.    Data was 
collected by the pulmonary 
rehabilitation team and 
inputted into a database by the 
team leader/administrator 
 
Details on age, severity, gender 
and medical history were not 
available, all participants had a  
diagnosis of COPD and were 
eligible for PR. 
 
ANOVA with post hoc Tukey 
HSD comparisons were 
undertaken. 
(p<0.001), and baseline and 12 months 
(p<0.001).  Figure 1c shows the PAM scores 
at the three timepoints. 
 
Limitations: secondary analysis of 
retrospective data, no control group, some 
data not available for all variables for each 
participant. 
Exemplar 4 - PAM as a tool to inform tailoring of targeted interventions 
Study Aim& Setting  Participants  Study Design & Sampling Methods& Analysis  Results & Limitations 
To determine PAM 
levels within a 
community stroke 
population, to 
develop and 
evaluate the 
feasibility and 
acceptability pf an 
20 participants who had had a 
stroke (in previous 12 months) 
and were living in the 
community under a stroke 
nursing team. 
 
Male 12, Female 18, mean age 
64 SD 11.51 
Study design and location: Multisite, two phase 
mixed method study (2013-2014), NHS Scotland 
(Fife, Lanarkshire, Highland) 
 
Study recruitment and sampling:  Participants 
identified through the stroke nursing teams and 
identified to take part in the study, from routine 
visits and care.  
Participants completed the 
PAM tool prior to a qualitative 
interview around their self-
management needs. 
 
  
The median PAM score was 76.4 (IQR 
10.93) (Level 4).  There were no significant 
differences in PAM Scores when comparing 
gender and Modified Rankin Scores (level 
of disability). 
 
Despite the quantitative PAM scores, 
qualitative interviews reflected 
intervention based 
on patient 
activation and 
tailoring of stroke 
self-management 
support. 32 
 
 
Time since stroke:  1-6mths = 
12; 7-12 mths =  8   
cognitive impairment (n=12), 
MRS moderate to mod severe 
disability (n=10) 
 
 
 
Phase 1 (development of intervention) 
 
Phase 1 involved interviews with patients to identify 
PAM levels and self-management needs (through 
qualitative interviews) and development of a self-
management intervention.   The ‘intervention’ 
comprised a ‘tailored self-management action plan 
(in booklet form) created based on PAM score and 
person-centred goal setting. 
 
Phase 2 involved piloting the self-management 
intervention (reported elsewhere). 32  
 
Ethical approval:  12/WS/0103 West of Scotland 
Committee 3 
characteristics associated with lower PAM 
levels (e.g. Levels 1 and 2, as shown in 
Figure 1). 
 
Limitations: small sample size,  
convenience sample, PAM score not 
assessed following intervention because of 
short intervention period, sample selection 
by stroke nurses (possible gatekeeping). 
 
